Palvella Therapeutics Inc (NASDAQ: PVLA)’s stock price has dropped by -4.10 in relation to previous closing price of 26.56. Nevertheless, the company has seen a gain of 4.39% in its stock price over the last five trading days. globenewswire.com reported 2025-04-23 that Quantitative analysis of medical claims indicates an estimated 44,553 to 92,967 diagnosed U.S. patients with lymphatic malformations (LMs) with cutaneous involvement
Is It Worth Investing in Palvella Therapeutics Inc (NASDAQ: PVLA) Right Now?
Company’s 36-month beta value is -0.00.Analysts have differing opinions on the stock, with 7 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PVLA is 6.56M, and currently, short sellers hold a 1.56% ratio of that floaft. The average trading volume of PVLA on April 25, 2025 was 73.50K shares.
PVLA’s Market Performance
PVLA’s stock has seen a 4.39% increase for the week, with a -6.60% drop in the past month and a 96.07% gain in the past quarter. The volatility ratio for the week is 8.32%, and the volatility levels for the past 30 days are at 11.49% for Palvella Therapeutics Inc The simple moving average for the past 20 days is 4.31% for PVLA’s stock, with a 47.30% simple moving average for the past 200 days.
Analysts’ Opinion of PVLA
Many brokerage firms have already submitted their reports for PVLA stocks, with Chardan Capital Markets repeating the rating for PVLA by listing it as a “Buy.” The predicted price for PVLA in the upcoming period, according to Chardan Capital Markets is $50 based on the research report published on April 09, 2025 of the current year 2025.
Stifel, on the other hand, stated in their research note that they expect to see PVLA reach a price target of $45. The rating they have provided for PVLA stocks is “Buy” according to the report published on March 26th, 2025.
Scotiabank gave a rating of “Sector Outperform” to PVLA, setting the target price at $50 in the report published on March 07th of the current year.
PVLA Trading at 6.95% from the 50-Day Moving Average
After a stumble in the market that brought PVLA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.98% of loss for the given period.
Volatility was left at 11.49%, however, over the last 30 days, the volatility rate increased by 8.32%, as shares sank -8.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +57.71% upper at present.
During the last 5 trading sessions, PVLA rose by +4.39%, which changed the moving average for the period of 200-days by +239.15% in comparison to the 20-day moving average, which settled at $24.42. In addition, Palvella Therapeutics Inc saw 112.25% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PVLA starting from JENKINS GEORGE M, who purchase 2,490 shares at the price of $20.27 back on Apr 09 ’25. After this action, JENKINS GEORGE M now owns 13,516 shares of Palvella Therapeutics Inc, valued at $50,472 using the latest closing price.
JENKINS GEORGE M, the Director of Palvella Therapeutics Inc, purchase 2,500 shares at $20.13 during a trade that took place back on Apr 09 ’25, which means that JENKINS GEORGE M is holding 183,171 shares at $50,325 based on the most recent closing price.
Stock Fundamentals for PVLA
The total capital return value is set at -0.18. Equity return is now at value -68.21, with -39.93 for asset returns.
Currently, EBITDA for the company is -13.12 million with net debt to EBITDA at 6.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.82.
Conclusion
In a nutshell, Palvella Therapeutics Inc (PVLA) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
